OnCore Login

Return to Trial Database

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Status

Enrollment Closed

Cancer Type(s)

Melanoma

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Publications

Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma
  • S Rapisuwon, RD Carvajal, G Ansstas, KK Tsai, LF Hernandez-Aya, S Khan, S Chandra, JW Harbour, JA Sosman, A Daud, C Decatur, D Ozisik, M Tan, MB Atkins, SP Patel
Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma
  • S Rapisuwon, SP Patel, RD Carvajal, LF Hernandez-Aya, K Tsai, S Chandra, MT Tan, A Daud, JA Sosman, MB Atkins

Trial Locations

All sites in which the trial HCRN-MEL17-309 being conducted in.
Columbia University Irving Medical Center
Georgetown Lombardi Comprehensive Cancer Center
MD Anderson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
UC San Francisco
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278